The global antibody-drug conjugates (ADCs) market was valued at approximately USD 11.29 billion in 2023, with projections indicating a compound annual growth rate (CAGR) of 9.2% from 2024 to 2030. This growth is largely driven by a robust research and development (R&D) pipeline within the sector, which is enabling the continuous development of new and innovative ADCs. Additionally, the...